top of page

Ultragenyx's Emil Kakkis on this week's Angelman syndrome data, rare disease treatment modalities, and more

Emil Kakkis summarizes Ultragenyx's Angelman syndrome update at AAN, discusses use cases for various treatment modalities, and gives his take on the current state of rare disease drug development.



コメント


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page